Crossfire Oncology is focused on developing innovative therapies for cancer treatment, leveraging its proprietary technology platform. The company specializes in harnessing the power of its unique approach to target and destroy cancer cells while minimizing damage to healthy tissues. This technology is designed to enhance the efficacy of existing cancer treatments and improve patient outcomes by utilizing a combination of targeted therapies and advanced delivery mechanisms.

The company's pipeline includes a range of product candidates that are in various stages of development, aimed at addressing different types of cancer. Crossfire Oncology's scientific foundation is built on a deep understanding of tumor biology and the mechanisms of cancer progression, which informs their research and development efforts. By integrating cutting-edge scientific insights with their proprietary technologies, Crossfire aims to create transformative therapies that can significantly impact the landscape of cancer treatment.

Netherlands

Aberrant functioning of kinases is known to be an important driver in cancer. Targeting hereof has proven to be extremely successful and has already revolutionized the management of numerous types of cancer.

At Crossfire Oncology we approach kinases from three different angles: inhibitors, degraders, and degrader antibody conjugates. This tailored approach allows us to design kinase targeting drugs that aim to maximize the therapeutic benefit for cancer patients.

Crossfire Oncology

Company Details